Newsroom.
GC Biopharma USA Appoints New Head of Market Access to Leadership Team
GC Biopharma, USA the commercial operations and distribution company of GC Biopharma, has announced the appointment of industry veteran Ms. Mary Longarini to its senior leadership team. Ms. Longarini comes to GC Biopharma, USA with more than 20 years in senior leadership positions within the plasma industry. She has led teams and achieved success with various product launches throughout her career. Both her US plasma industry and commercial start-up experience have been instrumental in building the market access framework for GC Biopharma USA, Inc. Ms. Longarini's appointment further contributes to GC's vision of establishing excellence within its US-based operations.
Mr. WJ Lee, CEO of GC Biopharma USA, stated, "Our goal is to assemble the top experts from within the plasma and pharmaceutical industry to build a strong platform for our growth and success. With the pending launch of our IVIG 10% product, Ms. Longarini strengthens our position in the US marketplace."
About GC Biopharma
GC Biopharma USA, Inc. headquartered in Fort Lee, NJ, established its sales, marketing, and business operations in 2018 to serve customers and patients throughout the US. Our foundation is built on our parent company GC Biopharma's expertise, a leading biopharmaceutical company delivering plasma therapies and vaccines worldwide. With GC Biopharma USA, Inc., GC Biopharma will further extend its footprint, bringing its expertise and legacy to the United States.
This press release may contain forward-looking statements that express GC Biopharma and GC Biopharma USA, Inc.'s management's current beliefs and expectations. Such views do not represent any guarantee by either entity or its government of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma and GC Biopharma USA, Inc. undertake no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements they may make, except as required by law or stock exchange rule.
